Funds
Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs
Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies
Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund
Sofinnova Partners, biotech acceleration fund, BioClec, Forth Therapeutics, Signadori Bio, venture capital, pharmaceutical backing
Bain Capital Raises $3 Billion for Fourth Life Sciences Fund to Support Innovative Biotech Startups
Bain Capital, Life Sciences Fund, Biotech Startups, Venture Capital, Funding
Decheng Capital Seeks $700 Million for Fifth Life Sciences Fund Amidst VC Surge
Decheng Capital, Life Sciences Fund, Venture Capital, Biotechnology, Investment Firm